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Abstract: Pharmacists have a valuable role in the management of allergic rhinitis (AR) at the
community pharmacy level. This role has been reported extensively in numerous papers. However,
a systematic review of the available literature and a comprehensive analysis of the outcomes has not
been published. This systematic review aimed to evaluate the impact of interventions developed by
pharmacists on clinical AR outcomes. A thorough search was performed in three electronic databases,
including studies published between January 2000 and June 2019. After the selection process, only
three articles met the inclusion criteria and were further analysed. Despite the scarcity of the available
studies, in all of them was clear that the pharmacist plays a pivotal role in the management of AR,
significantly improving the patients’ quality of life and symptom control. This systematic review also
stresses the utmost importance to investigate and report practices and interventions developed by
pharmacists using measurable outcomes.
Keywords: allergic rhinitis; community pharmacy; pharmacist
1. Introduction
Allergic rhinitis (AR), commonly referred to as hayfever, is a chronic upper respiratory condition
resulting from inflammation of the nasal mucosa. The common symptoms of AR include sneezing,
rhinorrhoea and nasal congestion, induced by an immunological response following exposure to
allergens such as pollen, house dust mites, moulds and animal dander in sensitised individuals [1].
While AR is often portrayed as a nuisance or trivial condition, the reality is that uncontrolled AR
is a disabling and intrusive disease: disabling in terms of its chronicity, and intrusive in terms of
its symptom burden and impact on patients’ lives and the lives of their families. Poorly controlled
AR can have a substantial negative impact on a patient’s quality of life, including impairments in
concentration, work productivity, social interactions and sleep. It is a significant cause of morbidity
and imposes a high socioeconomic burden due to the direct treatment costs and the indirect costs due
to absenteeism from the workplace and reduced productivity at work [2–4]. The impact of poorly
controlled AR can also extend into co-existing asthma, where it can worsen asthma symptom control
and increase the risk of exacerbations or flare-ups [5].
The socioeconomic and health burden of poorly controlled AR on individuals and society
can be minimised with optimal AR management strategies, that encompass patients education,
including allergen minimisation strategies, pharmacotherapy and the addition of allergen-specific
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immunotherapy in severe cases of AR [6]. AR can be optimally managed in the primary care setting;
however, there are several challenges encountered by both general practitioners (GPs) and community
pharmacists [7,8]. For GPs, AR is becoming more challenging to diagnose, and management is often
complicated by polysensitization and the presence of both allergic and non-allergic disease components.
For community pharmacists, the fact that the majority of patients who present to community pharmacy
have “self-diagnosed” their condition [9–13] and/or self-select over-the-counter AR treatments in a
community pharmacy, without seeking pharmacist advice are major challenges [7,8,14,15].
The non-governmental organization Allergic Rhinitis and its Impact on Asthma (ARIA) issued
specific guidelines for the management of AR in the community pharmacy, first in 2004 [14] with a
recent update [16]. Other guidelines have also been issued by other scientific societies, including the
Standards of Care Committee of the British Society of Allergy and Clinical Immunology, albeit without
specific recommendations to pharmacists [17]. While pharmacists cannot confirm a diagnosis of AR,
they have a key role to play in the management of AR, by ensuring their patients have received a
diagnosis, are guided to optimal treatment for their nasal symptoms, and/or are referred to their GPs
if needed.
Pharmacists can interview patients and determine whether they require a referral and further
medical investigation [16]. They play a critical role in engaging patients who self-select over-the-counter
AR medication, which is often associated with suboptimal management [9,13,18–21]. In a study by
Lourenço et al. (2014), uncontrolled AR was identified in 87% of pharmacy patients [22]. This was
further confirmed in a recent Australian study where almost 85% of people who self-selected their AR
medication, made a suboptimal choice [13]. For patients who self-manage their AR and bypass health
care professionals (HCPs), it’s of the utmost importance to recapture their attention. Since patients
have reported that they discuss their medication with their pharmacist more often than with their
physician [18], the role of the pharmacist in AR management needs to be promoted. Within the context
of health care delivery, the role of the pharmacist includes the provision of medication counselling
and disease education, monitoring of treatment response, provision of lifestyle recommendation
and establishment of therapeutic goals [16,23]. The provision of pharmacist counselling and their
interactions with patients have been shown to reduce the likelihood of experiencing medication adverse
effects [24], increase adherence to therapy [25], and improve health outcomes [26]. It is crucial for
pharmacists to harness these skills and incorporate them into AR management to identify and optimise
poorly controlled AR.
While there is a large body of literature available regarding the management of AR within the
community pharmacy setting, to date, no systematic review has evaluated community pharmacists’
intervention in AR management. This systematic review aims to evaluate the impact of community
pharmacists’ interventions on clinical AR outcomes among adult patients.
2. Materials and Methods
2.1. Data Sources and Searches
This systematic review was performed according to the methodology recommended by the
PRISMA guidelines [27] from January 2018 to June 2019. The research was conducted using three
electronic databases: PubMed, Web of Science and Cochrane Central Register of Controlled Trials.
Table 1 shows the specific research strategy adopted; the keywords that were used included MeSH and
general terms relating to pharmacy, pharmacists and AR (“pharmacy” [MeSH], “community pharmacy”,
“pharmaceutical services” [MeSH], “pharmaceutical care”, “pharmacist”, “clinical pharmacy”, “allergic
rhinitis” [MeSH] and “hay fever”).
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Table 1. Search strategy adopted for this systematic review.
PubMed Web of Science Cochrane Central Register of Controlled Trials
Search Result Search Result Search Result
1 Pharmacy 369,988 TOPIC:(Pharmacy) 39,661 Pharmacy 12,793
2 Community pharmacy 25,790 TOPIC:(Community Pharmacy) 7911 Community pharmacy 1619
3 Pharmaceutical services 75,375 TOPIC:(Pharmaceutical services) 5499 Pharmaceutical services 1332
4 Pharmaceutical care 94,491 TOPIC:(Pharmaceutical care) 16,051 Pharmaceutical care 4205
5 Pharmacist * 33,612 TOPIC:(Pharmacist) 30,192 Pharmacist * 3914
6 Clinical pharmacy 87,664 TOPIC:(Clinical Pharmacy) 9309 Clinical pharmacy 10,802
7 1 OR 2 OR 3 OR 4 OR 5 OR 6 439,230 1 OR 2 OR 3 OR 4 OR 5 OR 6 74,702 1 OR 2 OR 3 OR 4 OR 5 OR 6 17,638
8 Allergic rhinitis 29,036 TOPIC:(Allergic Rhinitis) 22,524 Allergic rhinitis 6743
9 Hay fever 15,255 TOPIC:(Hay fever) 4196 Hay fever 714
10 8 OR 9 30,080 8 OR 9 25,647 8 OR 9 6977
11 7 AND 10 260 7 AND 10 117 7 AND 10 33
* a PubMed notation to indicate that the search included “pharmacist” and “pharmacists” as seach keywords.
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2.2. Study Selection
To be included in the systematic review, the studies had to meet the following inclusion criteria:
(1) published between January 2000 and June 2019; (2) written in Portuguese, English, Spanish or
French; (3) original article/investigation (primary literature); and (4) report the results of community
pharmacists interventions in AR. All articles that did not meet the mentioned inclusion criteria were not
considered. No limitation regarding the age of the participants was considered. References obtained
from different databases were compared to identify and remove duplicates.
2.3. Data Synthesis
The titles and abstracts of all articles obtained from the database search were screened to identify
potentially relevant articles (which fulfilled the inclusion criteria). Non-relevant articles were deleted
while potentially relevant articles identified were obtained. The full text of the eligible studies was
read and evaluated, considering the objectives of this review. All non-original and non-experimental
studies that did not report the clinical results from the implemented intervention or interventions
that were not exclusively implemented by community pharmacists were also excluded. Additionally,
potentially relevant studies in the bibliographic references of the selected studies of interest were
searched. The studies identified were reviewed by two investigators (J.J. and O.L.).
The relevant information that was extracted from each eligible article, was (1) the source (author
and year of publication), (2) the country where the intervention was performed, (3) the objective of the
intervention, (4) the type of study (5) the outcomes assessed, (6) the tools used for outcome assessment,
(7) the number of participants (patients with AR, pharmacists and pharmacies), (8) the intervention
results, and (9) study limitations.
2.4. Quality Assessment
For assessment of study quality and risk of bias, we applied the ‘Risk of Bias’ tool described
in the Cochrane Review Group Handbook and the STROBE statement checklists (available on
https://www.strobe-statement.org).
3. Results
Electronic searching from the different databases resulted in a total of 478 citations, of which 78
duplicates were removed. Their titles and abstracts were then read to assess their agreement with the
initially defined inclusion criteria, which resulted in 31 studies. Of these, 28 were excluded, which
resulted in three studies included in the systematic review. This process is illustrated in Figure 1.
The three intervention studies [10,28,29] that were included evaluated the improvement of
patients’ quality of life (QoL) after intervention by community pharmacists. This assessment was
performed using validated tools, namely the Mini Rhinoconjunctivitis Quality of Life Questionnaire
(Mini RQLQ ©), the Visual Analog Scales (VAS) [10,28] and also the SF-12v2 Health Survey [29]
(validated questionnaire for Bulgaria). Table 2 summarises the information extracted from each study
included in this systematic review.
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Figure 1. Selection of the studies to be included in the systematic review.
e intervention study conducted by Arsoy et al. focused on AR ducation, including avoidance
of allergen exposure, counselling on medication and training on the administration technique of nas l
m dication [10]. The study involved two visits: baseline and 6 weeks post-baseline for each patient.
The study conducted by O’Connor et al. [28] compared two interventions de elop d by community
ph rm cists. In the first, participants defined their relevant goals and strategies relating to their AR; in
the second, participants had their goals and strategies defined by a pharmacist. Although pharmacies
were randomis d, the study did not have a control group per se, as both gr ups had support from
community pharmacists. For each pati nt, the interventio involv d a series of thre visits: baseline,
on -week form baseline and 6 weeks from baseline.
Both studies used the Mini RQLQ© to assess the QoL of the pati ts before and after
the interventions.
The Mini RQLQ© scores were signific ntly reduced between the pharmacy visits resulting in
statistically significant QoL improvem nts [10,28]. However, th study c nducted by O’Connor, J. et al.
reported that there was no significant improvement between the pharmacist-defined goals group and
t e patient-defined goals group (F (2.35) = 1.03, p > 0.05).
The study by To orova et al. [29] explored the impact f pharmaceutical care and patient
counselling on QoL, as measured by the SF-12v2 Health Survey. The baseline survey involved patients
with pronounced AR symptoms seeking medical advice in the pharmacy. A follow-up survey of the
patients QoL was performed after the intervention and dispensing of the appropriate OTC product
according to ARIA guidelines (no period between visits is referred). The study showed an improvement
in patients’ QoL in various aspects (physical and mental health and social functions).
Regarding the severity of symptoms, both the Arsoy G. et al. [10] and O’Connor, J. et al. [28] studies
achieved a significant decrease in the severity of symptoms VAS scores. However, the former reported
a decrease in both groups (intervention and control) [10] while in the latter a greater statistically
significant decrease was reported in the group where pharmacists set patients’ targets [28].
Pharmacy 2020, 8, 80 6 of 9
Table 2. Summary of studies that met the inclusion criteria and were included in the systematic review.
Author & Year
of Publication Country Objective Type of Study Outcomes
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Todorova, A. et al.
(2017) [29] Bulgaria (Varna)
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patients with AR
Small number of
patients, only city of
Varna
* In total, 32 patients in the intervention group and 31 in the control group; # 26 patients in the patient-defined goals group and 21 patients in the pharmacist-defined goals group.
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4. Discussion and Conclusions
This systematic review highlights the paucity of research exploring pharmacist interventions in
AR management and draws to attention the urgency of the requirement for further reseach in this field,
especially given the burden caused by sub-optimal management of AR internationally [3,30]. Although
it is difficult to evaluate the impact of community pharmacists’ interventions on clinical AR outcomes
among adult patients given the limited amount of studies identified as a part of this review, it is with
certainty that we can say the the role of the pharmacist in AR management has been underoptimised
thus far. In the current health care environment where AR is frequently undertreated, underdiagnosed
and patient self-selection is profound, the role of the pharmacist is more important than ever [31,32].
A major limitation of this review was the scarcity of intervention studies in AR in the community
pharmacy setting, as well as the limited quality of existing studies. The most profound limitation across
all the three studies was the limited number of participants, both pharmacists and patients. Similarly,
the studies were conducted were confined to specific geographical areas and not necessarily applicable
to wider health care settings international. O’Connor et al., also has limitations of not having a control
group and focussing on OAH use, whose overuse is currently associated with poorer AR outcomes
and is only recommended in the most mildest of AR cases [16,33].
However, despite the limited number of pharmacy interventions evaluated, this review has
shown that pharmacists play a crucial role in helping patients minimise their AR symptoms, providing
information and advice on treatment and monitoring outcomes. From these studies it can be concluded
that interventions by community pharmacists in the management of AR can significantly improve
patients’ QoL while also improving disease control; however, further research in this field is needed.
Further interventions are imperative to fully understand the pharmacist’s role in the management of
AR since the community pharmacy is the venue of choice for patients to receive counselling regarding
AR and often the only place where patients seek healthcare for their AR.
Patients with AR have needs that are not being met by current practices, e.g., diagnosis is absent
in many cases, and there is inadequate counselling and treatment selection by pharmacists. These facts
may be related to pharmacists’ lack of knowledge about ARIA guidelines [11,34] and ultimately lead
to lack of disease control. These unmet needs are opportunities for pharmacists to intervene in order to
improve patient’s QoL and disease management, thereby reducing the burden of AR.
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